Caladrius Biosciences, Inc. (NASDAQ:CLBS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Wednesday.

According to Zacks, “Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials. Caladrius Biosciences, Inc., formerly known as NeoStem, Inc., is headquartered in New York. “

Other equities research analysts also recently issued reports about the company. HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Caladrius Biosciences in a research report on Wednesday, September 6th. ValuEngine raised Caladrius Biosciences from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st.

Caladrius Biosciences (CLBS) opened at 3.56 on Wednesday. The company has a 50-day moving average price of $3.83 and a 200-day moving average price of $4.35. Caladrius Biosciences has a one year low of $2.65 and a one year high of $7.79.

Caladrius Biosciences (NASDAQ:CLBS) last released its earnings results on Thursday, August 10th. The biotechnology company reported ($0.88) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.96) by $0.08. Caladrius Biosciences had a negative return on equity of 180.68% and a negative net margin of 84.10%. Equities analysts anticipate that Caladrius Biosciences will post ($2.42) earnings per share for the current fiscal year.

WARNING: This news story was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/13/caladrius-biosciences-inc-clbs-stock-rating-lowered-by-zacks-investment-research.html.

A number of hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in Caladrius Biosciences by 2.8% during the second quarter. Vanguard Group Inc. now owns 155,380 shares of the biotechnology company’s stock worth $723,000 after buying an additional 4,163 shares in the last quarter. KCG Holdings Inc. grew its position in Caladrius Biosciences by 74.6% during the first quarter. KCG Holdings Inc. now owns 36,291 shares of the biotechnology company’s stock worth $183,000 after buying an additional 15,501 shares in the last quarter. Finally, Renaissance Technologies LLC grew its position in Caladrius Biosciences by 34.3% during the first quarter. Renaissance Technologies LLC now owns 97,552 shares of the biotechnology company’s stock worth $491,000 after buying an additional 24,900 shares in the last quarter. 6.47% of the stock is currently owned by institutional investors and hedge funds.

Caladrius Biosciences Company Profile

Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.

Receive News & Stock Ratings for Caladrius Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences Inc. and related stocks with our FREE daily email newsletter.